pep-04939 v1 CC-BY-SA-4.0
Blood-pressure-lowering peptide (GPVGPA)
A small peptide that blocks an enzyme called ACE, which the body uses to raise blood pressure, so blocking it helps bring blood pressure down. Experimental, not an approved drug.
status
Someone proposed this peptide.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
A computer predicted how the peptide binds to its target.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
Someone else ran the same prediction and got the same result.
A second contributor repeated the computation on their own hardware and the scores matched.
The peptide was actually made in a lab.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
The peptide was tested on its target in a lab.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
prediction metrics
ipTM0.719
pTM0.516
avg pLDDT81.8
ranking score0.798
STRUCTURE · PEP-04939 × ACE
ranking0.798
target interface 4.5Å peptide drag rotate · ctrl+scroll zoom · right-click pan
sequence
156
GPVGPA
details
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.719258725643158 | boltz-2 |
| ranking score | 0.7980877161026001 | boltz-2 |
▸3-letter notation
Gly-Pro-Val-Gly-Pro-Ala
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | colabfold_nvidia |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-25 |
▸citationbibtex
peptidemodel (2026). Blood-pressure-lowering peptide (GPVGPA) (pep-04939, v1). PeptideModel. https://peptidemodel.com/card/pep-04939
@peptide{pep04939,
sequence = {GPVGPA},
target = {ace},
author = {peptidemodel},
year = {2026},
status = {computed}
} related peptides
references
discussion
sign in to comment